Functionalized Lineage Tracing Can Enable the Development of Homogenization-Based Therapeutic Strategies in Cancer

The therapeutic landscape across many cancers has dramatically improved since the introduction of potent targeted agents and immunotherapy. Nonetheless, success of these approaches is too often challenged by the emergence of therapeutic resistance, fueled by intratumoral heterogeneity and the immense evolutionary capacity inherent to cancers. To date, therapeutic strategies have attempted to outpace the evolutionary tempo of cancer but frequently fail, resulting in lack of tumor response and/or relapse. This realization motivates the development of novel therapeutic approaches which constrain evolutionary capacity by reducing the degree of intratumoral heterogeneity prior to treatment. Systematic development of such approaches first requires the ability to comprehensively characterize heterogeneous populations over the course of a perturbation, such as cancer treatment. Within this context, recent advances in functionalized lineage tracing approaches now afford the opportunity to efficiently measure multimodal features of clones within a tumor at single cell resolution, enabling the linkage of these features to clonal fitness over the course of tumor progression and treatment. Collectively, these measurements provide insights into the dynamic and heterogeneous nature of tumors and can thus guide the design of homogenization strategies which aim to funnel heterogeneous cancer cells into known, targetable phenotypic states. We anticipate the development of homogenization therapeutic strategies to better allow for cancer eradication and improved clinical outcomes.

[1]  J. C. Love,et al.  Mitochondrial variant enrichment from high-throughput single-cell RNA sequencing resolves clonal populations , 2022, Nature Biotechnology.

[2]  James M. McFarland,et al.  Microenvironment drives cell state, plasticity, and drug response in pancreatic cancer , 2021, Cell.

[3]  X. Zhang,et al.  Replication stress response defects are associated with response to immune checkpoint blockade in nonhypermutated cancers , 2021, Science Translational Medicine.

[4]  J. Lohr,et al.  Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma , 2021, Nature Cell Biology.

[5]  Jeffrey J. Quinn,et al.  Lineage Recording Reveals the Phylodynamics, Plasticity and Paths of Tumor Evolution , 2021, bioRxiv.

[6]  Z. Modrušan,et al.  Identifying transcriptional programs underlying cancer drug response with TraCe-seq , 2021, Nature Biotechnology.

[7]  A. Regev,et al.  Cycling cancer persister cells arise from lineages with distinct programs , 2021, Nature.

[8]  Kaitlyn E. Johnson,et al.  Multifunctional barcoding with ClonMapper enables high-resolution study of clonal dynamics during tumor evolution and treatment , 2021, Nature Cancer.

[9]  L. Zhong,et al.  Small molecules in targeted cancer therapy: advances, challenges, and future perspectives , 2021, Signal Transduction and Targeted Therapy.

[10]  Xiaohui S. Xie,et al.  Lineage tracing and analog recording in mammalian cells by single-site DNA writing , 2021, Nature Chemical Biology.

[11]  Jeffrey J. Quinn,et al.  Single-cell lineages reveal the rates, routes, and drivers of metastasis in cancer xenografts , 2020, Science.

[12]  Sydney M. Shaffer,et al.  Variability within rare cell states enables multiple paths towards drug resistance , 2020, Nature Biotechnology.

[13]  Kirsten L. Frieda,et al.  Imaging cell lineage with a synthetic digital recording system , 2020, Science.

[14]  S. Konermann,et al.  CloneSifter: enrichment of rare clones from heterogeneous cell populations , 2020, BMC biology.

[15]  Samantha A. Morris,et al.  Next-Generation Lineage Tracing and Fate Mapping to Interrogate Development. , 2020, Developmental cell.

[16]  S. Dawson,et al.  Non-genetic mechanisms of therapeutic resistance in cancer , 2020, Nature Reviews Cancer.

[17]  D. Landau,et al.  Integrating genetic and non-genetic determinants of cancer evolution by single-cell multi-omics , 2020, Nature Reviews Genetics.

[18]  R. Cantón,et al.  Collateral sensitivity associated with antibiotic resistance plasmids , 2020, bioRxiv.

[19]  C. Coman,et al.  A multi-omics analysis reveals the unfolded protein response regulon and stress-induced resistance to folate-based antimetabolites , 2020, Nature Communications.

[20]  S. Orkin,et al.  An Engineered CRISPR-Cas9 Mouse Line for Simultaneous Readout of Lineage Histories and Gene Expression Profiles in Single Cells , 2020, Cell.

[21]  Mateusz Kciuk,et al.  Mechanisms of Multidrug Resistance in Cancer Chemotherapy , 2020, International journal of molecular sciences.

[22]  J. Wilmott,et al.  Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition , 2020, Nature Communications.

[23]  K. Polyak,et al.  Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. , 2020, Cancer cell.

[24]  Lin Tang Integrating lineage tracing and single-cell analysis , 2020, Nature Methods.

[25]  Amy E. Decker,et al.  Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer , 2020, Nature Genetics.

[26]  H. Ouzon-Shubeita,et al.  Structural insights into the promutagenic bypass of the major cisplatin-induced DNA lesion. , 2020, The Biochemical journal.

[27]  T. Stankovic,et al.  Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial , 2020, Leukemia.

[28]  Einar Bjarki Gunnarsson,et al.  Understanding the role of phenotypic switching in cancer drug resistance. , 2020, Journal of theoretical biology.

[29]  Allon M. Klein,et al.  Lineage tracing on transcriptional landscapes links state to fate during differentiation , 2018, Science.

[30]  Charles C. Bell,et al.  Principles and mechanisms of non-genetic resistance in cancer , 2019, British Journal of Cancer.

[31]  Catherine J. Wu,et al.  Clonal dynamics in chronic lymphocytic leukemia. , 2019, Blood advances.

[32]  Mark W. Budde,et al.  In situ readout of DNA barcodes and single base edits facilitated by in vitro transcription , 2019, Nature Biotechnology.

[33]  A. Bardelli,et al.  Adaptive mutability of colorectal cancers in response to targeted therapies , 2019, Science.

[34]  Mariella G. Filbin,et al.  An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma , 2019, Cell.

[35]  J. Ursini-Siegel,et al.  An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy , 2019, Nature Communications.

[36]  Samantha A. Morris,et al.  CellTag Indexing: genetic barcode-based sample multiplexing for single-cell genomics , 2019, Genome Biology.

[37]  Martin J. Aryee,et al.  Lineage Tracing in Humans Enabled by Mitochondrial Mutations and Single-Cell Genomics , 2019, Cell.

[38]  Jacob G. Scott,et al.  Resistance to ALK targeting therapies as a gradual Darwinian adaptation to inhibitor specific selective pressures , 2018, bioRxiv.

[39]  Howard Y. Chang,et al.  Single-cell lineage tracing by endogenous mutations enriched in transposase accessible mitochondrial DNA , 2018, bioRxiv.

[40]  L. Galluzzi,et al.  Linking cellular stress responses to systemic homeostasis , 2018, Nature Reviews Molecular Cell Biology.

[41]  Evert Bosdriesz,et al.  An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential , 2018, Cell.

[42]  Wei Cheng,et al.  New insights from the widening homogeneity perspective to target intratumor heterogeneity , 2018, Cancer communications.

[43]  G. Mayhew,et al.  Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal , 2018, Cell.

[44]  Mi Ni Huang,et al.  In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors , 2017, bioRxiv.

[45]  James A. Gagnon,et al.  Simultaneous single-cell profiling of lineages and cell types in the vertebrate brain , 2018, Nature Biotechnology.

[46]  J. Balko,et al.  TGF-b inhibition enhances chemotherapy action against triple-negative breast cancer , 2018 .

[47]  Jason W. Locasale,et al.  Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. , 2017, Cell reports.

[48]  D. Wheeler,et al.  Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma. , 2017, European urology.

[49]  Wei Chen,et al.  Polylox barcoding reveals haematopoietic stem cell fates realized in vivo , 2017, Nature.

[50]  William A. Flavahan,et al.  Epigenetic plasticity and the hallmarks of cancer , 2017, Science.

[51]  G. Mills,et al.  Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers , 2017, Science Translational Medicine.

[52]  Jacob G. Scott,et al.  Somatic clonal evolution: A selection-centric perspective. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[53]  Nicholas Navin,et al.  Tumor evolution: Linear, branching, neutral or punctuated? , 2017, Biochimica et biophysica acta. Reviews on cancer.

[54]  N. McGranahan,et al.  Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.

[55]  Davide Prandi,et al.  Clonal evolution of chemotherapy-resistant urothelial carcinoma , 2016, Nature Genetics.

[56]  Sue Chua,et al.  High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. , 2016, Cancer discovery.

[57]  Gábor E. Tusnády,et al.  A comprehensive survey of the mutagenic impact of common cancer cytotoxics , 2016, Genome Biology.

[58]  Shohei Koyama,et al.  Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.

[59]  Raja R Srinivas,et al.  Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution , 2016, Cell.

[60]  G. Getz,et al.  Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition , 2016, Nature Medicine.

[61]  G. Getz,et al.  Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F. , 2016, The New England journal of medicine.

[62]  Hanlee P. Ji,et al.  Pan-cancer analysis of the extent and consequences of intratumor heterogeneity , 2015, Nature Medicine.

[63]  Xuemei Lu,et al.  Extremely high genetic diversity in a single tumor points to prevalence of non-Darwinian cell evolution , 2015, Proceedings of the National Academy of Sciences.

[64]  Martin A. Nowak,et al.  Mutations driving CLL and their evolution in progression and relapse , 2015, Nature.

[65]  M. Ibrahim,et al.  Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp , 2015, Cancer Cell International.

[66]  Charles Swanton,et al.  Clinical management of breast cancer heterogeneity , 2015, Nature Reviews Clinical Oncology.

[67]  A. Pisco,et al.  Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: ‘What does not kill me strengthens me' , 2015, British Journal of Cancer.

[68]  Joshua M. Korn,et al.  Studying clonal dynamics in response to cancer therapy using high-complexity barcoding , 2015, Nature Medicine.

[69]  Andrei Kucharavy,et al.  Targeting the Adaptability of Heterogeneous Aneuploids , 2015, Cell.

[70]  P. Majumder,et al.  Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition , 2015, Nature Communications.

[71]  C. Curtis,et al.  A Big Bang model of human colorectal tumor growth , 2015, Nature Genetics.

[72]  Evis Sala,et al.  Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis , 2015, PLoS medicine.

[73]  H P Soyer,et al.  A stress-induced early innate response causes multidrug tolerance in melanoma , 2014, Oncogene.

[74]  Yu Cao,et al.  Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing , 2014, Science.

[75]  Luca Magnani,et al.  Poised epigenetic states and acquired drug resistance in cancer , 2014, Nature Reviews Cancer.

[76]  Samra Turajlic,et al.  BRAF Inhibitors Induce Metastasis in RAS Mutant or Inhibitor-Resistant Melanoma Cells by Reactivating MEK and ERK Signaling , 2014, Science Signaling.

[77]  C. Sander,et al.  Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy , 2014, Clinical Cancer Research.

[78]  A. McKenna,et al.  Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy. , 2014, Cancer cell.

[79]  Steven J. M. Jones,et al.  Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma , 2014, Science.

[80]  K. Robasky,et al.  The role of replicates for error mitigation in next-generation sequencing , 2013, Nature Reviews Genetics.

[81]  K. Cimprich,et al.  Causes and consequences of replication stress , 2013, Nature Cell Biology.

[82]  L. Cantley,et al.  What a tangled web we weave: emerging resistance mechanisms to inhibition of the phosphoinositide 3-kinase pathway. , 2013, Cancer discovery.

[83]  Amy Brock,et al.  Non-Darwinian dynamics in therapy-induced cancer drug resistance , 2013, Nature Communications.

[84]  C. Zahnow,et al.  The future of epigenetic therapy in solid tumours—lessons from the past , 2013, Nature Reviews Clinical Oncology.

[85]  E. Mroz,et al.  MATH, a novel measure of intratumor genetic heterogeneity, is high in poor-outcome classes of head and neck squamous cell carcinoma. , 2013, Oral oncology.

[86]  J. Balko,et al.  TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer. , 2013, The Journal of clinical investigation.

[87]  M. Deininger,et al.  Pushing the limits of targeted therapy in chronic myeloid leukaemia , 2012, Nature Reviews Cancer.

[88]  Jian Jin,et al.  Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer , 2012, Cell.

[89]  A. Tolcher,et al.  The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer , 2012, Clinical Cancer Research.

[90]  Carlo C. Maley,et al.  Clonal evolution in cancer , 2012, Nature.

[91]  E. Lander,et al.  Theory Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells , 2011 .

[92]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[93]  E. Lander,et al.  Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells , 2011, Cell.

[94]  Gaetano Rocco,et al.  Epithelial to Mesenchymal Transition by TGFβ-1 Induction Increases Stemness Characteristics in Primary Non Small Cell Lung Cancer Cell Line , 2011, PloS one.

[95]  P. Ding,et al.  BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. , 2010, Leukemia research.

[96]  Ling Xia,et al.  Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. , 2009, Cancer research.

[97]  Laura M. Heiser,et al.  Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. , 2009, Cancer research.

[98]  P. Valent Imatinib-resistant chronic myeloid leukemia (CML): Current concepts on pathogenesis and new emerging pharmacologic approaches , 2007, Biologics : targets & therapy.

[99]  Peter A. Jones,et al.  The Epigenomics of Cancer , 2007, Cell.

[100]  L. Boise,et al.  Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. , 2006, Blood.

[101]  I. Christensen,et al.  In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. , 1997, British Journal of Cancer.

[102]  H. Suzuki,et al.  Differential induction of chromosomal aberrations by topoisomerase inhibitors in cultured Chinese hamster cells. , 1994, Biological & pharmaceutical bulletin.

[103]  B. Hill Potential of continuous tumour cell lines for establishing patterns of cross-resistance and collateral sensitivity in vitro. , 1986, Drugs under experimental and clinical research.